title: The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.
authors.forename: Eleanor J
authors.initials: EJ
authors.lastname: Cheadle
authors.forename: Lauren
authors.initials: L
authors.lastname: Sidon
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Dovedi
authors.forename: Monique H M
authors.initials: MH
authors.lastname: Melis
authors.forename: Waleed
authors.initials: W
authors.lastname: Alduaij
authors.forename: Tim M
authors.initials: TM
authors.lastname: Illidge
authors.forename: Jamie
authors.initials: J
authors.lastname: Honeychurch
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D006801:Humans; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: CD20; DAMP; cell death; lymphoma; monoclonal antibody